Search results
Results From The WOW.Com Content Network
On Thursday, Intellia Therapeutics Inc (NASDAQ:NTLA) outlined its strategic priorities for 2025, emphasizing the acceleration of late-stage programs for NTLA-2002 and nex-z. These therapies target ...
That was true on Oct. 24 when Intellia Therapeutics (NASDAQ: NTLA) announced some positive new clinical trial data only to see its stock slide by 18% -- and the price hasn't fully recovered as of yet.
Based on these factors, Intellia Therapeutics won't get a boost to its stock price anywhere close to what Wall Street predicts in the next 12 months. That alone doesn't mean the stock isn't a buy ...
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise ...
Shares of biotech Intellia Therapeutics (NASDAQ: NTLA) are down by around 33% over the past 30 days, amid the publication of some new data from an early stage clinical trial on Nov. 16 and its ...
Biotech and pharmaceutical companies in the New York metropolitan area represent a significant and growing economic component of the New York metropolitan area, [1] [2] the most populous combined statistical area in the United States [3] and one of the most populous megacities in the world.
*Stock Advisor returns as of October 21, 2024 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Intellia Therapeutics.
Do the numbers hold clues to what lies ahead for the stock? Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -19.78% and 33.35%, respectively, for the quarter ended ...